Molecular targets versus models for new antiepileptic drug discovery

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Animal models have played a key role in the discovery and characterization of all marketed antiepileptic drugs (AED). The conventional wisdom is that the standard animal screening models are becoming obsolete because they fail to identify compounds that act in mechanistically new ways and as a result do not offer therapeutic advantages over presently available agents. In fact, far from only detecting me-too drugs, the models often uncover compounds with distinctive profiles of activity in various types of epilepsy and in addition have unexpected efficacy in non-epilepsy conditions, such as neuropathic pain, bipolar disorder, and migraine. Moreover, the animal models - because they are unbiased with respect to mechanism - provide an opportunity to uncover drugs that act in new ways and through new targets, such as α2δ and SV2A. In vitro testing is not likely to replace screening in animal models because in vitro systems cannot model the specific pharmacodynamic actions required for seizure protection, and do not assess bioavailability and brain accessibility.

Original languageEnglish (US)
Pages (from-to)22-28
Number of pages7
JournalEpilepsy Research
Volume68
Issue number1
DOIs
StatePublished - Jan 2006
Externally publishedYes

Fingerprint

Drug Discovery
Anticonvulsants
Animal Models
Somatoform Disorders
Neuralgia
Migraine Disorders
Bipolar Disorder
Pharmaceutical Preparations
Biological Availability
Epilepsy
Seizures
Brain
In Vitro Techniques
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neurology

Cite this

Molecular targets versus models for new antiepileptic drug discovery. / Rogawski, Michael A.

In: Epilepsy Research, Vol. 68, No. 1, 01.2006, p. 22-28.

Research output: Contribution to journalArticle

@article{dfafbbadb04b49c197477776fb81e0c2,
title = "Molecular targets versus models for new antiepileptic drug discovery",
abstract = "Animal models have played a key role in the discovery and characterization of all marketed antiepileptic drugs (AED). The conventional wisdom is that the standard animal screening models are becoming obsolete because they fail to identify compounds that act in mechanistically new ways and as a result do not offer therapeutic advantages over presently available agents. In fact, far from only detecting me-too drugs, the models often uncover compounds with distinctive profiles of activity in various types of epilepsy and in addition have unexpected efficacy in non-epilepsy conditions, such as neuropathic pain, bipolar disorder, and migraine. Moreover, the animal models - because they are unbiased with respect to mechanism - provide an opportunity to uncover drugs that act in new ways and through new targets, such as α2δ and SV2A. In vitro testing is not likely to replace screening in animal models because in vitro systems cannot model the specific pharmacodynamic actions required for seizure protection, and do not assess bioavailability and brain accessibility.",
author = "Rogawski, {Michael A}",
year = "2006",
month = "1",
doi = "10.1016/j.eplepsyres.2005.09.012",
language = "English (US)",
volume = "68",
pages = "22--28",
journal = "Epilepsy Research",
issn = "0920-1211",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Molecular targets versus models for new antiepileptic drug discovery

AU - Rogawski, Michael A

PY - 2006/1

Y1 - 2006/1

N2 - Animal models have played a key role in the discovery and characterization of all marketed antiepileptic drugs (AED). The conventional wisdom is that the standard animal screening models are becoming obsolete because they fail to identify compounds that act in mechanistically new ways and as a result do not offer therapeutic advantages over presently available agents. In fact, far from only detecting me-too drugs, the models often uncover compounds with distinctive profiles of activity in various types of epilepsy and in addition have unexpected efficacy in non-epilepsy conditions, such as neuropathic pain, bipolar disorder, and migraine. Moreover, the animal models - because they are unbiased with respect to mechanism - provide an opportunity to uncover drugs that act in new ways and through new targets, such as α2δ and SV2A. In vitro testing is not likely to replace screening in animal models because in vitro systems cannot model the specific pharmacodynamic actions required for seizure protection, and do not assess bioavailability and brain accessibility.

AB - Animal models have played a key role in the discovery and characterization of all marketed antiepileptic drugs (AED). The conventional wisdom is that the standard animal screening models are becoming obsolete because they fail to identify compounds that act in mechanistically new ways and as a result do not offer therapeutic advantages over presently available agents. In fact, far from only detecting me-too drugs, the models often uncover compounds with distinctive profiles of activity in various types of epilepsy and in addition have unexpected efficacy in non-epilepsy conditions, such as neuropathic pain, bipolar disorder, and migraine. Moreover, the animal models - because they are unbiased with respect to mechanism - provide an opportunity to uncover drugs that act in new ways and through new targets, such as α2δ and SV2A. In vitro testing is not likely to replace screening in animal models because in vitro systems cannot model the specific pharmacodynamic actions required for seizure protection, and do not assess bioavailability and brain accessibility.

UR - http://www.scopus.com/inward/record.url?scp=30144443464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30144443464&partnerID=8YFLogxK

U2 - 10.1016/j.eplepsyres.2005.09.012

DO - 10.1016/j.eplepsyres.2005.09.012

M3 - Article

C2 - 16377151

AN - SCOPUS:30144443464

VL - 68

SP - 22

EP - 28

JO - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

IS - 1

ER -